Loading...
Essential thrombocythemia (ET) is a clonal myeloproliferative neoplasm affecting platelet production, complicated by microvascular and large vessel thrombosis as well as bleeding due to platelet dysfunction and acquired von Willebrand syndrome.
To examine whether antithrombotic therapy is safe and effective for ET, investigators conducted a systematic review of 24 nonrandomized studies encompassing 6153 ET patients; no randomized, controlled trials were found.
A history of thrombosis was reported in up to 46% of patients and bleeding in up to 26%. Antiplatelet therapy had a median relative risk for thrombosis of 0.74 (range, 0.26–3.48); any bleeding, 1.95 (0.48–11.04); and major bleeding, 1.3 (0.48–5.17).
C…